CIP2A coordinates phosphosignaling, mitosis, and the DNA damage response

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Human cancers exhibit shared dependencies on signaling pathways, mitotic activity, and DNA damage response.
• The oncoprotein CIP2A (cancerous inhibitor of protein phosphatase 2A) plays a central role in regulating these cancer cell characteristics.

Purpose of the Study:

• To elucidate the mechanisms by which CIP2A coordinates cancer cell signaling, mitosis, and DNA damage survival.
• To investigate the role of the CIP2A-TopBP1 complex in DNA repair and chromosomal stability.
• To highlight the clinical significance of CIP2A as a disease driver and therapeutic target, particularly in basal-like triple-negative breast cancer (BL-TNBC).

Main Methods:

• Investigating CIP2A's role in controlling cancer cell phosphoproteomes through inhibition of protein phosphatase 2A (PP2A).
• Analyzing the direct interaction between CIP2A and the DNA damage response protein TopBP1 (topoisomerase II-binding protein 1).
• Assessing CIP2A's essentiality in mitotic cells with defects in homologous recombination (HR) DNA repair, such as BRCA mutants.

Main Results:

• CIP2A regulates cancer cell phosphoproteomes by inhibiting PP2A.
• CIP2A directly interacts with TopBP1, facilitating the entry of DNA-damaged cells into mitosis.
• The CIP2A-TopBP1 complex is vital for clustering fragmented chromosomes during mitosis and is essential for HR-defective cancer cells.
• CIP2A is identified as a key driver in basal-like triple-negative breast cancer (BL-TNBC).

Conclusions:

• CIP2A is a critical regulator coordinating key cancer cell processes including signaling, mitosis, and DNA damage response.
• The CIP2A-TopBP1 interaction is essential for maintaining genomic stability, particularly in cancers with compromised DNA repair pathways.
• CIP2A represents a significant therapeutic target for a broad spectrum of cancers, including BL-TNBC.